Austrianova

13/08/2026

Austrianova is pleased to announce its latest co-operation programme aiming to develop a physiological treatment for diabetes.

Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell expertise through a research collaboration with Avaí Bio and Austrianova’s JV Company, Insulinova, aimed at advancing an encapsulated cell therapy for diabetes.

22/07/2026

Austrianova is pleased to announce Insulinova’s latest news.

/PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for...

16/07/2026

The Austrianova team met with a delegation of distinguished visitors from the Medical University, Graz, Austria and from A*Star for productive and interesting discussions today during a site visit to our Singapore facility.

09/06/2026

Austrianova CPO, Rahul Pawa, was invited to TISTR International Conference 2026.

21/05/2026

Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy

19/05/2026

Austrianova management were invited guests at todays event "Supercharging Healthspan and Joyspan: the State-of-Art Longevity Technology and Therapeutics” held at The Meeting Point @ JTC LaunchPad. The event featured a session on Start Ups and investment opportunities as well as sessions on Women’s Health and Men’s Health.

23/04/2026

We welcome Thomas to our Board!

SINGAPORE - April 21, 2026 - SG Austria/Austrianova (the SG Austria group comprising of Austrianova Singapore, Austrianova Thailand and Anovade UG) (the “Company”) is pleased to announce the appointment of C. Thomas Paschall, CEO and Founder of Checkmate Capital, to the Board of the SG Austria g...

22/04/2026

Austrianova and AVAI Bio at the forefront of cell-based therapies for anti-aging and longevity using Cell-in-a-Box encapsulation

From encapsulated cell therapies to gene-driven breakthroughs, a new wave of biotech is targeting the biology of aging.

08/04/2026

https://www.stocktitan.net/news/AVAI/

"Recent news has highlighted Avant’s joint venture with SGAustria Pte. Ltd. to form Insulinova, Inc., which is intended to develop cell-based therapies for type 1 and some insulin-dependent type 2 diabetes using insulin-producing cells combined with encapsulation technology. Other announcements cover the creation and progress of Klothonova, a 50/50 joint venture with Austrianova that is developing encapsulated Klotho-producing cell therapies for age-related conditions, including cardiovascular and neurodegenerative diseases."

Read the latest AVAI news on Avant Technologies, including joint ventures for diabetes and Klotho therapies, AI-based Vision AI updates, and corporate actions. Latest AVAI news updated today, April 7.

03/04/2026

Austrianova wishes every a Happy G🐰🐰d Friday!